Welcome!

News Feed Item

United Therapeutics Corporation Reports 2013 Fourth Quarter And Annual Financial Results

SILVER SPRING, Md., Feb. 25, 2014 /PRNewswire/ -- 

  • Total Annual Revenues of $1.1 billion
  • Annual Earnings per Share of $3.49 per Basic Share or $3.28 per Diluted Share
  • Annual Non-GAAP Earnings of $10.88 per Basic Share or $10.23 per Diluted Share

United Therapeutics Corporation (NASDAQ: UTHR) today announced its financial results for the fourth quarter and year ended December 31, 2013.

"United Therapeutics continued to deliver strong results in 2013, reflecting growing demand for our Remodulin®, Tyvaso® and Adcirca® products," remarked Martine Rothblatt, Ph.D., United Therapeutics' Chairman and Chief Executive Officer. "In addition we successfully brought a fourth product, Orenitram, to FDA approval and continued enrolling patients in two pivotal trials with the goal of demonstrating that our oral prostacyclin analogues reduce morbidity and mortality in patients with pulmonary arterial hypertension. We feel blessed to be able to help PAH patients with medicines that have leading shares of their market segments, and are excited about our pipeline of several promising new therapies."

Total revenues for the quarter ended December 31, 2013 were $289.0 million, up from $243.8 million for the quarter ended December 31, 2012. Net loss for the quarter ended December 31, 2013 was $30.3 million or $0.60 net loss per basic share, compared to net income of $83.3 million or $1.65 per basic share for the quarter ended December 31, 2012. For the year ended December 31, 2013, we had net income of $174.6 million, or $3.49 per basic share and $3.28 per diluted share, compared to $304.4 million, or $5.84 per basic share and $5.71 per diluted share, for the year ended December 31, 2012. Non-GAAP earnings(1) for the quarter ended December 31, 2013, were $160.2 million or $3.19 per basic share, compared to $84.6 million or $1.67 per basic share for the quarter ended December 31, 2012.   Non-GAAP earnings for the year ended December 31, 2013, were $544.7 million or $10.88 per basic share, compared to $383.2 million or $7.36 per basic share for the year ended December 31, 2012.

________________________

(1)    See definition of non-GAAP earnings, a non-GAAP financial measure, and a reconciliation of net income to non-GAAP earnings below.  

Operating Results

Revenues

The table below summarizes the components of revenues (in thousands):

 


Three Months Ended
December 31,


Year Ended
December 31,


2013


2012


2013


2012

Cardiopulmonary products:








Remodulin

$

119,865



$

116,214



$

491,179



$

457,969


Tyvaso

114,385



86,036



438,793



325,614


Adcirca

52,047



38,182



176,972



122,540


Other

2,720



3,385



10,040



9,953


Total revenues

$

289,017



$

243,817



$

1,116,984



$

916,076


 

Revenues for the quarter ended December 31, 2013 increased by $45.2 million compared to the quarter ended December 31, 2012. The growth in revenues corresponded to the continued increase in the number of patients being treated with our cardiopulmonary products.

Expenses

The table below summarizes research and development expense by major project and non-project component (in thousands):

 


Three Months Ended
December 31,


Year Ended
December 31,


2013


2012


2013


2012

Project and non-project:








Cardiopulmonary

$

32,242



$

30,892



$

116,137



$

122,350


Share-based compensation expense (benefit)

76,422



(3,722)



134,706



11,237


Other

12,888



10,306



48,505



39,800


Total research and development expense

$

121,552



$

37,476



$

299,348



$

173,387


 

Share-based compensation.  The $80.1 million increase in share-based compensation expense for the quarter ended December 31, 2013 over the same quarter in 2012 reflects the 43 percent appreciation in the price of our common stock during the quarter ended December 31, 2013, compared to a 4 percent decline in our stock price for the same quarter in 2012.

The table below summarizes selling, general and administrative expense by major category (in thousands):

 


Three Months Ended
December 31,


Year Ended
December 31,


2013


2012


2013


2012

Category:








General and administrative

$

38,112



$

31,118



$

140,235



$

116,899


Sales and marketing

21,038



15,788



73,871



67,220


Share-based compensation expense (benefit)

98,028



(6,833)



179,904



17,627


Total selling, general and administrative expense

$

157,178



$

40,073



$

394,010



$

201,746


 

General and administrative. The $7.0 million increase in general and administrative expenses for the quarter ended December 31, 2013 compared to the same quarter in 2012 was attributable principally to increases of $3.1 million in professional and consulting fees and $1.2 million in salaries and related expenses as a result of general corporate growth during 2013.

Sales and marketing. The $5.3 million increase in sales and marketing expenses for the quarter ended December 31, 2013 compared to the same quarter in 2012 was driven by an increase of $3.2 million in marketing and advertising expenses, as well as a $1.8 million increase in salaries and related expenses due to the growth of our sales force.

Share-based compensation.  The $104.9 million increase in share-based compensation expense for the quarter ended December 31, 2013 compared to the same quarter in 2012 reflects the 43 percent appreciation in the price of our common stock during the quarter ended December 31, 2013, compared to a 4 percent decline in the price of our common stock for the same quarter in 2012.

Non-GAAP Earnings

Non-GAAP earnings is defined as net income, adjusted for the following non-cash charges, as applicable: (1) interest; (2) non-cash license fees; (3) depreciation and amortization; (4) impairment charges; and (5) share-based compensation (stock option, share tracking award and employee stock purchase plan expense). 

A reconciliation of net income to non-GAAP earnings is presented below (in thousands, except per share data):

 


Year Ended
December 31,


Three Months Ended
December 31,


2013


2012


2011


2010


2013


2012













Net income (loss), as reported

$

174,560



$

304,442



$

217,868



$

105,916



$

(30,314)



$

83,255


Add (subtract) non-cash charges
(benefits):












Interest expense

18,058



16,639



21,372



19,714



4,562



4,490


Non-cash license fees





37,049








Depreciation and amortization

31,259



27,145



20,535



17,919



7,753



7,290


Impairment charges



4,839





7,688






Share-based compensation 
    expense (benefit)

320,786



30,115



(15,715)



113,942



178,202



(10,453)


Non-GAAP earnings

$

544,663



$

383,180



$

281,109



$

265,179



$

160,203



$

84,582














Non-GAAP earnings per share:












Basic

$

10.88



$

7.36



$

4.92



$

4.72



$

3.19



$

1.67


Diluted

$

10.23



$

7.19



$

4.73



$

4.46



$

2.88



$

1.62














Weighted average number of
common shares outstanding:












Basic

50,076



52,093



57,163



56,142



50,281



50,503


Diluted

53,231



53,280



59,395



59,516



55,648



52,133














 

Conference Call

We will host a half-hour teleconference on Tuesday, February 25, 2014, at 9:00 a.m. Eastern Time. The teleconference is accessible by dialing 1-877-351-5881, with international callers dialing 1-970-315-0533.  A rebroadcast of the teleconference will be available for one week by dialing 1-855-859-2056, with international callers dialing 1-404-537-3406 and using access code 58833697.

This teleconference is also being webcast and can be accessed via our website at http://ir.unither.com/events.cfm.

About United Therapeutics

United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of unique medicinal products.

Non-GAAP Financial Information

This press release contains a financial measure, non-GAAP earnings, that does not comply with generally accepted accounting principles in the United States (GAAP). This measure supplements our financial results prepared in accordance with GAAP as reported below.

We use non-GAAP earnings to assist us in: (1) planning, including the preparation of our annual operating budget; (2) allocating resources in an effort to enhance the financial performance of our business; (3) evaluating the effectiveness of our operational strategies; and (4) assessing our capacity to fund capital expenditures and expand our business. We believe this non-GAAP financial measure improves investors' understanding of our financial results by excluding certain expenses that we do not consider when evaluating and comparing the performance of our core operations and making operating decisions. However, there are limitations in the use of this non-GAAP financial measure in that it excludes certain operating expenses that are recurring in nature. In addition, our calculation of this non-GAAP financial measure may differ from the methodology used by other companies. The presentation of this non-GAAP financial measure should not be considered in isolation or as a substitute for our financial results prepared in accordance with GAAP.  A reconciliation of net income, the most directly comparable GAAP financial measure, to non-GAAP earnings can be found in the table above under the heading, Non-GAAP Earnings.

Forward-looking Statements

Statements included in this press release that are not historical in nature are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, among others, our expectations about the growing demand for our products, the impact of the FDA's approval of Orenitram, the goal of our two pivotal trials of our oral prostacyclin analogues, and the potential of our pipeline to deliver promising new therapies. These forward-looking statements are subject to certain risks and uncertainties, such as those described in our periodic reports filed with the Securities and Exchange Commission, that could cause actual results to differ materially from anticipated results. Consequently, such forward-looking statements are qualified by the cautionary statements, cautionary language and risk factors set forth in our periodic reports and documents filed with the Securities and Exchange Commission,  including our most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K. We claim the protection of the safe harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements. We are providing this information as of February 25, 2014, and assume no obligation to update or revise the information contained in this press release whether as a result of new information, future events or any other reason. [uthr-g]

Orenitram is a trademark, and Remodulin and Tyvaso are registered trademarks, of United Therapeutics Corporation. 

Adcirca is a registered trademark of Eli Lilly and Company.

 

UNITED THERAPEUTICS CORPORATION

CONSOLIDATED STATEMENTS OF OPERATIONS

(In thousands, except per share data)



Three Months Ended December 31,


Year Ended December 31,


2013


2012


2013


2012

Revenues:








Net product sales

$

286,297



$

240,431



$

1,106,944



$

906,123


Other

2,720



3,386



10,040



9,953


Total revenue

289,017



243,817



1,116,984



916,076


Operating expenses:








Research and development

121,552



37,476



299,348



173,387


Selling, general and administrative

157,178



40,073



394,010



201,746


Cost of product sales

38,778



37,665



131,127



119,297


Total operating expenses

317,508



115,214



824,485



494,430


Operating (loss) income

(28,491)



128,603



292,499



421,646


Other (expense) income:








Interest income

1,111



716



3,827



3,941


Interest expense

(4,562)



(4,490)



(18,058)



(16,639)


Other, net

312



123



635



31,723


Total other (expense) income, net

(3,139)



(3,651)



(13,596)



19,025


(Losses) earnings before income taxes

(31,630)



124,952



278,903



440,671


Income tax benefit (expense)

1,316



(41,697)



(104,343)



(136,229)


Net (loss) income

$

(30,314)



$

83,255



$

174,560



$

304,442


Net (loss) income per common share:








Basic

$

(0.60)



$

1.65



$

3.49



$

5.84


Diluted

$

(0.60)



$

1.60



$

3.28



$

5.71


Weighted average number of common shares outstanding:








Basic

50,281



50,503



50,076



52,093


Diluted

50,281



52,133



53,231



53,280


 

 

SELECTED CONSOLIDATED BALANCE SHEET DATA

(In millions)



December 31,


2013


2012

Cash, cash equivalents and marketable securities (excluding restricted amounts of $5.4 million as
of December 31, 2013 and 2012)

$

1,136.7



$

784.9


Total assets

2,087.6



1,626.6


Total liabilities and temporary equity

828.3



542.6


Total stockholders' equity

1,259.3



1,084.0


 

SOURCE United Therapeutics Corporation

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
Today traditional IT approaches leverage well-architected compute/networking domains to control what applications can access what data, and how. DevOps includes rapid application development/deployment leveraging concepts like containerization, third-party sourced applications and databases. Such applications need access to production data for its test and iteration cycles. Data Security? That sounds like a roadblock to DevOps vs. protecting the crown jewels to those in IT.
Today most companies are adopting or evaluating container technology - Docker in particular - to speed up application deployment, drive down cost, ease management and make application delivery more flexible overall. As with most new architectures, this dream takes significant work to become a reality. Even when you do get your application componentized enough and packaged properly, there are still challenges for DevOps teams to making the shift to continuous delivery and achieving that reducti...
SYS-CON Events announced today that Interface Corporation will exhibit at the Japan External Trade Organization (JETRO) Pavilion at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Interface Corporation is a company developing, manufacturing and marketing high quality and wide variety of industrial computers and interface modules such as PCIs and PCI express. For more information, visit http://www.i...
SYS-CON Events announced today that mruby Forum will exhibit at the Japan External Trade Organization (JETRO) Pavilion at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. mruby is the lightweight implementation of the Ruby language. We introduce mruby and the mruby IoT framework that enhances development productivity. For more information, visit http://forum.mruby.org/.
DevOps at Cloud Expo, taking place October 31 - November 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA, is co-located with 21st Cloud Expo and will feature technical sessions from a rock star conference faculty and the leading industry players in the world. The widespread success of cloud computing is driving the DevOps revolution in enterprise IT. Now as never before, development teams must communicate and collaborate in a dynamic, 24/7/365 environment. There is no time to w...
In his session at @ThingsExpo, Greg Gorman is the Director, IoT Developer Ecosystem, Watson IoT, will provide a short tutorial on Node-RED, a Node.js-based programming tool for wiring together hardware devices, APIs and online services in new and interesting ways. It provides a browser-based editor that makes it easy to wire together flows using a wide range of nodes in the palette that can be deployed to its runtime in a single-click. There is a large library of contributed nodes that help so...
What is the best strategy for selecting the right offshore company for your business? In his session at 21st Cloud Expo, Alan Winters, U.S. Head of Business Development at MobiDev, will discuss the things to look for - positive and negative - in evaluating your options. He will also discuss how to maximize productivity with your offshore developers. Before you start your search, clearly understand your business needs and how that impacts software choices.
IBM helps FinTechs and financial services companies build and monetize cognitive-enabled financial services apps quickly and at scale. Hosted on IBM Bluemix, IBM’s platform builds in customer insights, regulatory compliance analytics and security to help reduce development time and testing. In his session at 21st Cloud Expo, Lennart Frantzell, a Developer Advocate with IBM, will discuss how these tools simplify the time-consuming tasks of selection, mapping and data integration, allowing devel...
SYS-CON Events announced today that Cedexis will exhibit at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Cedexis is the leader in data-driven enterprise global traffic management. Whether optimizing traffic through datacenters, clouds, CDNs, or any combination, Cedexis solutions drive quality and cost-effectiveness.
SYS-CON Events announced today that Mobile Create USA will exhibit at the Japan External Trade Organization (JETRO) Pavilion at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Mobile Create USA Inc. is an MVNO-based business model that uses portable communication devices and cellular-based infrastructure in the development, sales, operation and mobile communications systems incorporating GPS capabi...
While some developers care passionately about how data centers and clouds are architected, for most, it is only the end result that matters. To the majority of companies, technology exists to solve a business problem, and only delivers value when it is solving that problem. 2017 brings the mainstream adoption of containers for production workloads. In his session at 21st Cloud Expo, Ben McCormack, VP of Operations at Evernote, will discuss how data centers of the future will be managed, how th...
Why Federal cloud? What is in Federal Clouds and integrations? This session will identify the process and the FedRAMP initiative. But is it sufficient? What is the remedy for keeping abreast of cutting-edge technology? In his session at 21st Cloud Expo, Rasananda Behera will examine the proposed solutions: Private or public or hybrid cloud Responsible governing bodies How can we accomplish?
There is huge complexity in implementing a successful digital business that requires efficient on-premise and cloud back-end infrastructure, IT and Internet of Things (IoT) data, analytics, Machine Learning, Artificial Intelligence (AI) and Digital Applications. In the data center alone, there are physical and virtual infrastructures, multiple operating systems, multiple applications and new and emerging business and technological paradigms such as cloud computing and XaaS. And then there are pe...
SYS-CON Events announced today that MIRAI Inc. will exhibit at the Japan External Trade Organization (JETRO) Pavilion at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. MIRAI Inc. are IT consultants from the public sector whose mission is to solve social issues by technology and innovation and to create a meaningful future for people.
SYS-CON Events announced today that Keisoku Research Consultant Co. will exhibit at the Japan External Trade Organization (JETRO) Pavilion at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Keisoku Research Consultant, Co. offers research and consulting in a wide range of civil engineering-related fields from information construction to preservation of cultural properties. For more information, vi...